Xenon Pharmaceuticals Inc
3.25 %
-28.21 %
Yet to be announced
Company Overview
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders. The company's primary focus is on developing novel treatments for epilepsy and other central nervous system disorders.
Their lead product candidate, XEN496 (ezogabine), is being developed for the treatment of KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE). They are also developing XEN1101, a differentiated Kv7 potassium channel opener for the treatment of epilepsy and potentially other neurological disorders.
Revenue Sources
PassXenon Pharmaceuticals is a pre-revenue biotechnology company currently in research and development phase. The company is focused on developing treatments for neurological disorders, which is a halal business activity. As the company is pre-revenue and still in clinical trials, this criteria check is not applicable at this time.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
Based on the financial data provided, the company shows zero interest income and zero interest expense across all four quarters. The company appears to be funding its operations through equity rather than debt. As the company is still pre-revenue and in R&D phase, focusing on clinical trials for its drug candidates, the interest ratio checks are not applicable at this stage.
Operational Ethics
PassAfter reviewing the company's SEC filings, investor relations materials, and public information, there is no evidence of any significant ongoing associations with entities involved in human rights violations. The company's operations are primarily based in Canada and the United States, with no identified R&D centers or significant operations in Israel or direct ties to the Chinese Communist Party.
Comments